Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

作者：Hagop M. Kantarjian, Francis Joseph Giles, Lydia Wunderle, Kapil N. Bhalla, Susan Mary O'Brien, Barbara Waßmann, Chiaki Tanaka, Paul William Manley, P. Rae, William Leonard Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter F. Hoelzer, Maher X. Albitar, Margaret Han Dugan, Jörge E. Cortes, Leila Alland, Oliver Gerhard Ottmann · 发表于：New England Journal of Medicine · 年份：2006 · DOI：10.1056/nejmoa055104 · 被引用次数：1349 · 研究领域：Chronic Myeloid Leukemia Treatments、Eosinophilic Disorders and Syndromes、Myeloproliferative Neoplasms: Diagnosis and Treatment

BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50. METHODS: In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily. RESULTS: Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission. CONCLUSIONS: Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).